[Testing of bacterial mutants as potential vaccine strains].
The most important expectations made on the development of live vaccines are expounded, before a certain order is proposed according to which mutants should be tested. First, the characteristic features of the mutants should be determined with high accuracy, and the stability of these features should be established by repeated tests. Testing for harmlessness should not be undertaken until in vitro stability of a given mutant is established with certainty. The problems and possibilities associated to such tests are described by examples of Escherichia coli and Salmonella mutants. Immunogenic effectiveness of a given mutant has to be verified, after the harmlessness of the same mutant has been confirmed. Actual choice for potential use as vaccine strain will have to depend primarily on the results of an active protection experiment. The results obtained from Escherichia coli, Shigella, and Salmonella mutants are compared to those recorded from inactivated antigens.
D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology*; D004926:Escherichia coli / Q000235:genetics / Q000276:immunology*; D005819:Genetic Markers; D007928:Lethal Dose 50; D051379:Mice; D009154:Mutation; D012475:Salmonella / Q000235:genetics / Q000276:immunology*; D012764:Shigella sonnei / Q000235:genetics / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000276:immunology
D001428:Bacterial Vaccines; D005819:Genetic Markers; D014613:Vaccines, Attenuated
Untersuchungen zur Prüfung von bakteriellen Mutanten als potentielle Impfstämme.